In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Videos|July 22, 2017
Despite a Challenging Market, Tools Available for Independent Pharmacists
The challenges are well-documented, but additional acccess to data is assisting the independent pharmacist.
Advertisement
In this video clip taken at ThoughtSpot 2017, Charlie Le Bon, who is Director of Pharmacy Ownership with AmerisourceBergen, discusses the tools that are available to independent pharmacy owners to help them succeed, even in a challenging market.
Advertisement
Related to this article
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
3
Beyond Prescription Volume: Measuring the Pharmacist’s Value
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5